Milestone Pharmaceuticals Crecimiento futuro
Future controles de criterios 2/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Milestone Pharmaceuticals de 43% y 56.9% respectivamente, mientras que el BPA crecerá en un 45.6% al año.
Información clave
43.0%
Tasa de crecimiento de los beneficios
45.60%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 14.5% |
| Tasa de crecimiento de los ingresos | 56.9% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Good |
| Última actualización | 14 May 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
FDA Approval And Shift To Self Administered Care Will Reshape This Cardiovascular Opportunity
Catalysts About Milestone Pharmaceuticals Milestone Pharmaceuticals is a cardiovascular focused company centered on CARDAMYST, an etripamil nasal spray for on demand treatment of paroxysmal supraventricular tachycardia in adults. What are the underlying business or industry changes driving this perspective?
Payer Constraints On Self Administered PSVT Care Will Challenge Near Term Progress Yet Offer Upside
Catalysts About Milestone Pharmaceuticals Milestone Pharmaceuticals is a cardiovascular-focused biopharmaceutical company with an FDA approved, self-administered intranasal therapy, CARDAMYST, for acute treatment of paroxysmal supraventricular tachycardia in adults. What are the underlying business or industry changes driving this perspective?
Acute Cardiovascular Self Administration Will Reshape Treatment Patterns And Support Long Term Thesis
Catalysts About Milestone Pharmaceuticals Milestone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for acute cardiovascular conditions, including paroxysmal supraventricular tachycardia through its intranasal etripamil product, CARDAMYST. What are the underlying business or industry changes driving this perspective?Milestone: Downgrading To Sell As CARDAMYST Faces A Tough Reality
Summary Milestone Pharmaceuticals is downgraded to 'Sell' due to limited evidence supporting CARDAMYST's market adoption over generics. CARDAMYST's lack of statistically significant reduction in ER visits and high net price challenge its payer value proposition and peak share assumptions. My modeling, even with optimistic inputs, suggests MIST is overvalued with real downside risk, especially in a 'Bear' scenario where ROI is not achieved. Cash runway may be shorter than three years due to increased burn from CARDAMYST launch and AFib-RVR trial, raising dilution risk. Read the full article on Seeking AlphaDoes Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Does Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Here's Why Shareholders Should Examine Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO Compensation Package More Closely
Key Insights Milestone Pharmaceuticals' Annual General Meeting to take place on 13th of June CEO Joe Oliveto's total...Is Milestone Pharmaceuticals (NASDAQ:MIST) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...We're Interested To See How Milestone Pharmaceuticals (NASDAQ:MIST) Uses Its Cash Hoard To Grow
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Companies Like Milestone Pharmaceuticals (NASDAQ:MIST) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. By way of example, Milestone...What You Need To Know About Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Investor Composition
A look at the shareholders of Milestone Pharmaceuticals Inc. ( NASDAQ:MIST ) can tell us which group is most powerful...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 133 | -53 | 17 | -47 | 4 |
| 12/31/2027 | 29 | -129 | -82 | -106 | 6 |
| 12/31/2026 | 7 | -112 | -81 | -81 | 6 |
| 3/31/2026 | 2 | -68 | -51 | -51 | N/A |
| 12/31/2025 | 2 | -63 | -49 | -49 | N/A |
| 9/30/2025 | N/A | -58 | -43 | -43 | N/A |
| 6/30/2025 | N/A | -56 | -40 | -40 | N/A |
| 3/31/2025 | N/A | -52 | -34 | -34 | N/A |
| 12/31/2024 | N/A | -42 | -29 | -29 | N/A |
| 9/30/2024 | N/A | -43 | -32 | -32 | N/A |
| 6/30/2024 | N/A | -48 | -37 | -37 | N/A |
| 3/31/2024 | N/A | -55 | -42 | -41 | N/A |
| 12/31/2023 | 1 | -60 | -47 | -46 | N/A |
| 9/30/2023 | 5 | -59 | -50 | -49 | N/A |
| 6/30/2023 | 6 | -59 | -49 | -49 | N/A |
| 3/31/2023 | 6 | -59 | -53 | -52 | N/A |
| 12/31/2022 | 5 | -58 | -53 | -52 | N/A |
| 9/30/2022 | 2 | -62 | -52 | -52 | N/A |
| 6/30/2022 | N/A | -62 | -50 | -50 | N/A |
| 3/31/2022 | 15 | -44 | -35 | -35 | N/A |
| 12/31/2021 | 15 | -43 | -33 | -33 | N/A |
| 9/30/2021 | 15 | -35 | -30 | -30 | N/A |
| 6/30/2021 | 15 | -32 | -28 | -28 | N/A |
| 3/31/2021 | N/A | -46 | -45 | -45 | N/A |
| 12/31/2020 | N/A | -50 | -51 | -51 | N/A |
| 9/30/2020 | N/A | -60 | -59 | -59 | N/A |
| 6/30/2020 | N/A | -60 | -60 | -60 | N/A |
| 3/31/2020 | N/A | -61 | -55 | -54 | N/A |
| 12/31/2019 | N/A | -55 | N/A | -51 | N/A |
| 9/30/2019 | N/A | -47 | N/A | -42 | N/A |
| 6/30/2019 | N/A | -40 | N/A | -39 | N/A |
| 3/31/2019 | N/A | -29 | N/A | -31 | N/A |
| 12/31/2018 | N/A | -23 | N/A | -21 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que MIST siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: Se prevé que MIST siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que MIST siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (56.9% al año) de MIST crezcan más rápidamente que los del mercado US (11.7% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos (56.9% al año) de MIST crezcan más rápidamente que un 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de MIST se prevé que sea elevada dentro de 3 años.
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/24 00:27 |
| Precio de las acciones al final del día | 2026/05/22 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Milestone Pharmaceuticals Inc. está cubierta por 9 analistas. 6 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Patrick Trucchio | H.C. Wainwright & Co. |
| Brandon Folkes | H.C. Wainwright & Co. |
| Christopher Howerton | Jefferies LLC |